CoChat

Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen

Open access
Bergenstal, Richard M., Peyrot, Mark, Dreon, Darlene M., Aroda, Vanita R., Bailey, Timothy S., Brazg, Ronald L., Frias, Juan P., Johnson, Mary L., Klonoff, David C., Kruger, Davida F., Ramtoola, Shenaz, Rosenstock, Julio, Serusclat, Pierre, Weinstock, Ruth S., Naik, Ramachandra G., Shearer, David M., Zraick, Vivien, Levy, Brian L., on behalf of the Calibra Study Group, Behnke, Thomas, Beigi, Faramarz, Bernstein, Richard, Bhargava, Anuj, Bihan, Hélène, Bode, Bruce, Busch, Klaus, Cariou, Bertrand, Catargi, Bogdan, Chaicha-Brom, Tira, Chatterjee, Sudesna, Childs, Belinda, Clavel, Sylvaine, Collier, Andrew, Farret, Anne, Fogelfeld, Leon, Gress, Todd, Hanefeld, Markolf, Hollander, Priscilla, Huffman, David, Kelly, Christopher, Kipnes, Mark, Kwok, See, Leichter, Steven, Lévy, Marc, Lipetz, Robert, McCrimmon, Rory, McKnight, John, Molitch, Mark, Muse, Derek, Myers, Lyle, Odugbesan, Ola, Pfützner, Andreas, Pomposini, Daniel, Rajbhandari, Satyan, Rasouli, Neda, Reed, John, Riffer, Ernie, Riveline, Jean-Pierre, Robinson, Anthony, Schwarz, Peter, Simon, Jörg, Simon, William, Sood, Ajay, Stonesifer, Larry, Thivolet, Charles, Tripathy, Devjit, Vance, Carl, Welch, Michelle, Wynne, Alan, Zaidi, Reza · 2019 · Diabetes Technology & Therapeutics
Cited by 37

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: Barriers to mealtime insulin include complexity, fear of injections, and lifestyle interference. This multicenter, randomized controlled trial evaluated efficacy, safety, and self-reported outcomes in adults with type 2 diabetes, inadequately controlled on basal insulin, initiating and managing mealtime insulin with a wearable patch versus an insulin pen. Methods: Adults with type 2 diabetes ( n = 278, age: 59.2 ± 8.9 years), were randomized to patch ( n = 139) versus pen ( n = 139) for 48 weeks, with crossover at week 44. Baseline insulin was divided 1:1 basal: bolus. Using a pattern-control logbook, subjects adjusted basal and bolus insulin weekly using fasting and premeal glucose targets. Results: Glycated hemoglobin (HbA1c) change (least squares mean ± standard error) from baseline to week 24 (primary endpoint) improved ( P < 0.0001) in both arms, −1.7% ± 0.1% and −1.6% ± 0.1% for patch and pen (−18.6 ± 1.1 and −17.5 ± 1.1 mmol/mol), and was maintained at 44 weeks. The coefficient of variation of 7-point self-monitoring blood glucose decreased more ( P = 0.02) from baseline to week 44 for patch versus pen. There were no differences in adverse events, including hypoglycemia (three severe episodes per arm), and changes in weight and insulin doses. Subject-reported treatment satisfaction, quality of life, experience ratings at week 24, and device preferences at week 48 significantly favored the patch. Most health care providers preferred patch for mealtime insulin. Conclusions: Bolus insulin delivered by patch and pen using an algorithm-based weekly insulin dose titration significantly improved HbA1c in adults with type 2 diabetes, with improved subject and health care provider experience and preference for the patch.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2018.0298

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 37

Metadata

Authors
Bergenstal, R. M., Peyrot, M., Dreon, D. M., Aroda, V. R., Bailey, T. S., Brazg, R. L., Frias, J. P., Johnson, M. L., Klonoff, D. C., Kruger, D. F., Ramtoola, S., Rosenstock, J., Serusclat, P., Weinstock, R. S., Naik, R. G., Shearer, D. M., Zraick, V., Levy, B. L., on behalf of the Calibra Study Group, Behnke, T., Beigi, F., Bernstein, R., Bhargava, A., Bihan, H., Bode, B., Busch, K., Cariou, B., Catargi, B., Chaicha-Brom, T., Chatterjee, S., Childs, B., Clavel, S., Collier, A., Farret, A., Fogelfeld, L., Gress, T., Hanefeld, M., Hollander, P., Huffman, D., Kelly, C., Kipnes, M., Kwok, S., Leichter, S., Lévy, M., Lipetz, R., McCrimmon, R., McKnight, J., Molitch, M., Muse, D., Myers, L., Odugbesan, O., Pfützner, A., Pomposini, D., Rajbhandari, S., Rasouli, N., Reed, J., Riffer, E., Riveline, J.-P., Robinson, A., Schwarz, P., Simon, J., Simon, W., Sood, A., Stonesifer, L., Thivolet, C., Tripathy, D., Vance, C., Welch, M., Wynne, A., & Zaidi, R.
Venue
Diabetes Technology & Therapeutics
Published
2019-05
Volume
21
Issue
5
Pages
273-285
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W2942082371
Cited by
37
References
6
FWCI
3.61
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. https://app.cochat.ai/papers/10.1089/dia.2018.0298
The paper
Bergenstal, R. M., Peyrot, M., Dreon, D. M., Aroda, V. R., Bailey, T. S., Brazg, R. L., Frias, J. P., Johnson, M. L., Klonoff, D. C., Kruger, D. F., Ramtoola, S., Rosenstock, J., Serusclat, P., Weinstock, R. S., Naik, R. G., Shearer, D. M., Zraick, V., Levy, B. L., on behalf of the Calibra Study Group, . . . Zaidi, R. (2019). Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2018.0298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.